Lupin receives FDA approval for generic Triamcinolone Acetonide Ointment
New Delhi: Pharma major Lupin announced that it has received approval for its Triamcinolone Acetonide Ointment USP, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of Mylan Pharmaceuticals, Inc.’s (Mylan) Triamcinolone Acetonide Ointment, 0.1%.
Lupin’s Triamcinolone Acetonide Ointment USP, 0.1% is the generic version of Mylan’s Triamcinolone Acetonide Ointment, 0.1%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Triamcinolone Acetonide Ointment USP, 0.1% had annual sales of approximately USD 25.7 million in the US (IQVIA MAT June 2018).
Read Also: Lupin antimyotonic agent receives positive opinion from EMA
Lupin’s Triamcinolone Acetonide Ointment USP, 0.1% is the generic version of Mylan’s Triamcinolone Acetonide Ointment, 0.1%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Triamcinolone Acetonide Ointment USP, 0.1% had annual sales of approximately USD 25.7 million in the US (IQVIA MAT June 2018).
Read Also: Lupin antimyotonic agent receives positive opinion from EMA
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd